Opioid Use Disorder clinical trials
Showing 101–150 of 254 active trials. Describe your situation to see which ones you may be eligible for.
- Teaching Health Resilience in a Hospital Setting: A Peer-led Intervention
- VA Transitional Pain Service Study
- Optimizing Evidence-based HIV Prevention Targeting People Who Inject Drugs on PrEP
- Reducing Overdose and Substance Use-related Stigma by Training Non-substance-using Friends and Family Members of People Who Use Opioids to Be Harm Reduction Champions
- OMAR Opioid Use Disorder
- Mindfulness Texting for Medication Adherence and Chronic Pain Management
- Mapping Ibogaine Neural Dynamics in Opioid Use Disorder
- Postpartum Intervention for Mothers With Opioid Use Disorders (R33)
- Buprenorphine Implementation at Syringe Service Programs to Reduce Overdoses
- Effects of E-Cigarette Flavors on Adult E-Cigarette Users With Opioid Use Disorder
- AvertD Post-Approval Study
- EEG Biomarkers for OUD: Diagnostic, Prognostic, and Predictive Applications
- Opioid Use Disorder and Pain
- fMRI and Opioid Abstinence
- Sensing Physiological Symptoms of Opioid Withdrawal and Cravings in Patients With Opioid Use Disorder
- Adolescent Outcomes of Post-operative Opioid EXposure
- Integrating Brain, Neurocognitive, and Computational Tools in OUD
- Medications for Opioid Use Disorder Photosensitive Retinal Ganglion Cell Function, Sleep, and Circadian Rhythms: Implications for Treatment
- Predicting and Preventing Adverse Maternal and Child Outcomes of Opioid Use Disorder in Pregnancy
- Opioid Use Disorder in Pregnancy in Long-Term Maternal/Infant Outcomes
- Impact of Federal and State Medications for Opioid Use Disorder (MOUD) Policy Changes During the Pandemic
- Sensory Outcomes in Active Substance Users
- Emergency Medicine Peer Outreach Worker Engagement for Recovery
- Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
- Adversity, Brain and Opioid Use Study
- Exploration of Synaptotrophic Effects of Psilocybin in Opioid Use Disorder (OUD)
- Virtual Intelligence for Transformative Lifestyle Solutions in Pain
- Psilocybin on Brain Mechanisms of Motivation in OUD
- Measuring Acute Drug Demand in Humans
- Optimizing Pregnancy and Treatment Interventions for Moms 3.0
- Remotely Observed Methadone Evaluation II
- Using Facebook to Support Opioid Recovery Among American Indian Women
- Craving & Decision-Making
- Machine-Learning Prediction and Reducing Overdoses With EHR Nudges
- Assessing a Clinically-meaningful Opioid Withdrawal Phenotype
- Cannabis and Opioid Use Disorder
- The MOUD Plus Pilot: Counseling and Peer Support to Support Retention for Medically Complex Patients With Opioid Use Disorder Seen In Primary Care
- Interpersonal Brain Function in Opioid Use
- Improving Outcomes for Early Postpartum Mothers in Outpatient MOUD Treatment
- Leveraging Regulatory Flexibility for Methadone Take-Home Dosing to Improve Retention in Treatment for Opioid Use Disorder
- Longitudinal Neural Fingerprinting of Opioid-use Trajectories
- Evaluation of a Patient Decision Aid for Emergency Department Initiated Buprenorphine
- Pilot of Mailing Buprenorphine
- Methamphetamine and Troriluzole
- Implementing Contingency Management for Stimulant Use in Specialty Addiction Treatment Organizations
- Adjunctive Effects of Psilocybin and a Formulation of Buprenorphine
- A Study to Train a Machine Learning Algorithm for an Evaluation of the Use of Biometric Data Captured at the Wrist for the Identification of Acute Opioid Use Events and the Quantification of Opioid Withdrawal in Opioid Dependent Individuals
- Towards Testing the Effectiveness of Recovery Community Centers (RCCs)
- Reducing Opioid Mortality in Illinois
- Person-Centered Quality Measurement and Management in a System for Addictions Treatment in New York State (Project 3)
Guides for people searching for a trial
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.